PubRank

Martin Zeier

Author PubWeight™ 161.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011 6.35
2 Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N Engl J Med 2015 4.78
3 Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009 3.83
4 Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med 2007 3.35
5 Preparation of the dialysis patient for transplantation. Nephrol Dial Transplant 2002 2.10
6 Sustained low efficiency dialysis using a single-pass batch system in acute kidney injury - a randomized interventional trial: the REnal Replacement Therapy Study in Intensive Care Unit PatiEnts. Crit Care 2012 1.90
7 Glyoxalase-1 prevents mitochondrial protein modification and enhances lifespan in Caenorhabditis elegans. Aging Cell 2008 1.81
8 Renal sympathetic denervation therapy in the real world: results from the Heidelberg registry. Clin Res Cardiol 2013 1.78
9 Hantavirus infection. J Am Soc Nephrol 2005 1.60
10 Dysregulated cytokine responses during cytomegalovirus infection in renal transplant recipients. Transplantation 2008 1.55
11 Monitoring of NFAT-regulated gene expression in the peripheral blood of allograft recipients: a novel perspective toward individually optimized drug doses of cyclosporine A. Transplantation 2004 1.52
12 Malignancy in renal transplantation. J Am Soc Nephrol 2004 1.50
13 Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy. Transpl Int 2012 1.47
14 Urinary proinflammatory cytokine response in renal transplant recipients with polyomavirus BK viruria. Transplantation 2009 1.47
15 C. elegans as model for the study of high glucose- mediated life span reduction. Diabetes 2009 1.45
16 The Case: Renal failure in a male with Waldenström's macroglobulinemia. Kidney Int 2010 1.44
17 Long-term remission of paraprotein-induced immunotactoid glomerulopathy after high-dose therapy and autologous blood stem cell transplantation. Ann Hematol 2007 1.44
18 Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008 1.42
19 Individualized monitoring of nuclear factor of activated T cells-regulated gene expression in FK506-treated kidney transplant recipients. Transplantation 2010 1.41
20 The living kidney donor: giving life, avoiding harm. Nephrol Dial Transplant 2003 1.40
21 Improved rejection prophylaxis with an initially intensified dosing regimen of enteric-coated mycophenolate sodium in de novo renal transplant recipients. Transplantation 2011 1.39
22 Acute phase reaction to gadolinium-DTPA in dialysis patients. Nephrol Dial Transplant 2008 1.39
23 Immunogenicity and efficacy in hemodialysis patients of an AS03(A)-adjuvanted vaccine for 2009 pandemic influenza A(H1N1): a nonrandomized trial. Am J Kidney Dis 2011 1.27
24 Hantavirus infection: an emerging infectious disease causing acute renal failure. Kidney Int 2012 1.22
25 Sirolimus in renal transplantation. Nephrol Dial Transplant 2007 1.15
26 High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br J Haematol 2004 1.11
27 Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid. Mol Cancer Ther 2008 1.09
28 The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrol Dial Transplant 2011 1.09
29 Antifibrotic actions of mycophenolic acid. Clin Transplant 2006 1.08
30 Do AV fistulas contribute to cardiac mortality in hemodialysis patients? Semin Dial 2002 1.08
31 CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients. Pharmacogenet Genomics 2008 1.07
32 Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2005 1.07
33 Three-year outcomes following 1420 ABO-incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation 2015 1.05
34 Hantavirus causing hemorrhagic fever with renal syndrome enters from the apical surface and requires decay-accelerating factor (DAF/CD55). J Virol 2008 1.05
35 No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006 1.05
36 Results of renal transplantation using kidneys harvested from living donors at the University of Heidelberg. Nephrol Dial Transplant 2004 1.02
37 Metabolic control improves long-term renal allograft and patient survival in type 1 diabetes. J Am Soc Nephrol 2008 1.02
38 Intercellular communication by exchange of cytoplasmic material via tunneling nano-tube like structures in primary human renal epithelial cells. PLoS One 2011 1.00
39 Effects of peritoneal dialysis solutions low in GDPs on peritonitis and exit-site infection rates. Perit Dial Int 2008 1.00
40 A distinct subset of HLA-DR+-regulatory T cells is involved in the induction of preterm labor during pregnancy and in the induction of organ rejection after transplantation. Clin Immunol 2010 0.99
41 Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet 2010 0.97
42 A report of the Lisbon Conference on the care of the kidney transplant recipient. Transplantation 2007 0.97
43 Increased infarct size in uremic rats: reduced ischemia tolerance? J Am Soc Nephrol 2004 0.97
44 Color doppler ultrasonography in the diagnostic evaluation of renal allografts. Nephron Clin Pract 2006 0.96
45 Pathogenic old world hantaviruses infect renal glomerular and tubular cells and induce disassembling of cell-to-cell contacts. J Virol 2011 0.96
46 Late referral--a major cause of poor outcome in the very elderly dialysis patient. Nephrol Dial Transplant 2006 0.95
47 Role of FTY720 on M1 and M2 macrophages, lymphocytes, and chemokines in 5/6 nephrectomized rats. Am J Physiol Renal Physiol 2009 0.93
48 Age-related penetrance of hereditary atypical hemolytic uremic syndrome. Ann Hum Genet 2011 0.92
49 Unusual spindle cell squamous carcinoma in a renal transplant patient. Acta Derm Venereol 2004 0.92
50 Successful treatment of chronic tophaceous gout with infliximab (Remicade). Rheumatol Int 2005 0.91
51 Cyclosporin A toxicity of the renal allograft--a late complication and potentially reversible. Nephron 2002 0.90
52 Aquaporin-1 channel function is positively regulated by protein kinase C. J Biol Chem 2007 0.89
53 ABO-incompatible kidney transplantation enabled by non-antigen-specific immunoadsorption. Transplantation 2012 0.89
54 Glucose degradation products result in cardiovascular toxicity in a rat model of renal failure. Perit Dial Int 2010 0.89
55 An integrative approach for the transplantation of high-risk sensitized patients. Transplantation 2010 0.88
56 Role of podocytes in lupus nephritis. Nephrol Dial Transplant 2009 0.88
57 Nanotube action between human mesothelial cells reveals novel aspects of inflammatory responses. PLoS One 2011 0.87
58 Kidney and hypertension. Kidney Int Suppl 2002 0.87
59 Whole blood transcriptomics in cardiac surgery identifies a gene regulatory network connecting ischemia reperfusion with systemic inflammation. PLoS One 2010 0.87
60 Real-time contrast-enhanced sonography in renal transplant recipients. Clin Transplant 2006 0.86
61 Donor preconditioning with taurine protects kidney grafts from injury after experimental transplantation. J Surg Res 2007 0.86
62 Benfotiamine protects against peritoneal and kidney damage in peritoneal dialysis. J Am Soc Nephrol 2011 0.86
63 Sodium citrate anticoagulation during sustained low efficiency dialysis (SLED) in patients with acute renal failure and severely impaired liver function. Nephrol Dial Transplant 2007 0.86
64 DR(high+)CD45RA(-)-Tregs potentially affect the suppressive activity of the total Treg pool in renal transplant patients. PLoS One 2012 0.86
65 Effect of paricalcitol and calcitriol on aortic wall remodeling in uninephrectomized ApoE knockout mice. Am J Physiol Renal Physiol 2010 0.86
66 Pharmacokinetic and pharmacodynamic analysis of enteric-coated mycophenolate sodium: limited sampling strategies and clinical outcome in renal transplant patients. Br J Clin Pharmacol 2010 0.86
67 The long-term consequences of living-related or unrelated kidney donation. Nephrol Dial Transplant 2004 0.86
68 RAGE expression in the human peritoneal membrane. Nephrol Dial Transplant 2008 0.85
69 Management of severe recurrent focal segmental glomerulosclerosis through circulating soluble urokinase receptor modification. Am J Ther 2013 0.85
70 Characterization of a new Puumala virus genotype associated with hemorrhagic fever with renal syndrome. Virus Genes 2006 0.85
71 Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies. Transplantation 2006 0.85
72 Proton pump inhibitors interfere with the immunosuppressive potency of mycophenolate mofetil. Rheumatology (Oxford) 2010 0.84
73 Pharmacokinetics and pharmacodynamics of intensified versus standard dosing of mycophenolate sodium in renal transplant patients. Clin J Am Soc Nephrol 2010 0.84
74 In renal transplants with delayed graft function chemokines and chemokine receptor expression predict long-term allograft function. Transplantation 2010 0.84
75 The impact of type 2 diabetes on the outcome of localized renal cell carcinoma. World J Urol 2013 0.84
76 The influence of immunosuppression on the development of BK virus nephropathy-- does it matter? Nephrol Dial Transplant 2007 0.84
77 Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression. Transplantation 2008 0.84
78 Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors. Nephrol Dial Transplant 2004 0.84
79 Proteinuria after renal transplantation: pathogenesis and management. Nephrol Dial Transplant 2004 0.84
80 Pharmacodynamic cyclosporine A-monitoring: relation of gene expression in lymphocytes to cyclosporine blood levels in cardiac allograft recipients. Transpl Int 2007 0.83
81 Procalcitonin as marker of infection in patients with Goodpasture's syndrome is misleading. Nephrol Dial Transplant 2007 0.83
82 Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis. Transplantation 2005 0.83
83 Decreasing plasma soluble IL-1 receptor antagonist and increasing monocyte activation early post-transplant may be involved in pathogenesis of delayed graft function in renal transplant recipients. Clin Transplant 2009 0.83
84 Congestive heart failure due to systolic dysfunction: the Cinderella of cardiovascular management in dialysis patients. Semin Dial 2002 0.83
85 Impact of intraoperative parathyroid hormone levels on surgical results in patients with renal hyperparathyroidism. World J Surg 2005 0.82
86 Association of Kidney Graft Loss With De Novo Produced Donor-Specific and Non-Donor-Specific HLA Antibodies Detected by Single Antigen Testing. Transplantation 2015 0.82
87 The outcome of autologous stem cell transplantation in patients with plasma cell disorders and dialysis-dependent renal failure. Haematologica 2006 0.82
88 Cardiac biomarkers in haemodialysis patients: the prognostic value of amino-terminal pro-B-type natriuretic peptide and cardiac troponin T. Nephron Clin Pract 2007 0.82
89 Uremia aggravates left ventricular remodeling after myocardial infarction. Am J Nephrol 2010 0.82
90 When should post-transplantation proteinuria be attributed to the renal allograft rather than to the native kidney? Nat Clin Pract Nephrol 2007 0.82
91 Outcomes Following ABO-Incompatible Kidney Transplantation Performed After Desensitization by Nonantigen-Specific Immunoadsorption. Transplantation 2015 0.82
92 Living-donor kidney transplantation: risks of the donor--benefits of the recipient. Clin Transplant 2006 0.81
93 Immunosuppressive therapy and post-transplant malignancy. Nephrol Dial Transplant 2008 0.81
94 Transplantation of the type 1 diabetic patient: the long-term benefit of a functioning pancreas allograft. Clin J Am Soc Nephrol 2010 0.81
95 Chronic low-dose isotretinoin treatment limits renal damage in subtotally nephrectomized rats. J Mol Med (Berl) 2008 0.81
96 No gender-related differences in the severity of nephropathia epidemica, Germany. BMC Infect Dis 2013 0.81
97 Mutations in the BC-loop of the BKV VP1 region do not influence viral load in renal transplant patients. J Med Virol 2009 0.81
98 Enteric-coated mycophenolate sodium immunosuppression in renal transplant patients: efficacy and dosing. Transplant Rev (Orlando) 2012 0.81
99 Assessment of renal allograft fibrosis by transient elastography. Transpl Int 2013 0.81
100 Human RAGE antibody protects against AGE-mediated podocyte dysfunction. Nephrol Dial Transplant 2012 0.81
101 Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis. Atheroscler Suppl 2013 0.81
102 Protocol biopsy: what is the rationale and what is the evidence? Nephrol Dial Transplant 2003 0.81
103 Calcineurin inhibitors and NFAT-regulated gene expression. Clin Chim Acta 2011 0.80
104 Cellular effects of everolimus and sirolimus on podocytes. PLoS One 2013 0.80
105 Mobilization of circulating endothelial progenitor cells correlates with the clinical course of hantavirus disease. J Virol 2013 0.80
106 Safety and efficacy of intensified versus standard dosing regimens of enteric-coated mycophenolate sodium in de novo renal transplant patients. Transplantation 2011 0.80
107 Strong association of phenylalanine and tryptophan metabolites with activated cytomegalovirus infection in kidney transplant recipients. Hum Immunol 2011 0.80
108 Clostridium difficile diarrhoea in the immunosuppressed patient--update on prevention and management. Nephrol Dial Transplant 2004 0.80
109 Acute effects of calcineurin inhibitors on kidney allograft microperfusion visualized by contrast-enhanced sonography. Transplantation 2012 0.80
110 Dual regulation of renal Kir7.1 potassium channels by protein Kinase A and protein Kinase C. Biochem Biophys Res Commun 2008 0.80
111 AEB071--a promising immunosuppressive agent. Clin Transplant 2009 0.80
112 Genetic polymorphisms in IL-2, IL-10, TGF-β1, and IL-2RB and acute rejection in renal transplant patients. Clin Transplant 2014 0.80
113 Evidence for IFN-gamma up- and IL-4 downregulation late post-transplant in patients with good kidney graft outcome. Clin Transplant 2007 0.80
114 Contrast enhanced sonography shows superior microvascular renal allograft perfusion in patients switched from cyclosporine A to everolimus. Transplantation 2009 0.80
115 An oral load of the early glycation compound lactuloselysine fails to accumulate in the serum of uraemic patients. Nephrol Dial Transplant 2005 0.79
116 Cyclosporine-induced gingival overgrowth correlates with NFAT-regulated gene expression: a pilot study. J Clin Periodontol 2011 0.79
117 Recent outbreaks of hantavirus disease in Germany and in the United States. Kidney Int 2012 0.79
118 Disorders of phosphate metabolism--pathomechanisms and management of hypophosphataemic disorders. Best Pract Res Clin Endocrinol Metab 2003 0.79
119 Effect of insulin and glucose infusion on myocardial infarction size in uraemic rats. Basic Res Cardiol 2009 0.79
120 Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older. Ther Drug Monit 2011 0.79
121 Contrast-enhanced sonography as early diagnostic tool of chronic allograft nephropathy. Nephrol Dial Transplant 2006 0.79
122 Evaluation of hepatocyte growth factor as a sensitive marker for early detection of acute renal allograft rejection. Transplantation 2007 0.79
123 AcylMPAG plasma concentrations and mycophenolic acid-related side effects in patients undergoing renal transplantation are not related to the UGT2B7-840G>A gene polymorphism. Ther Drug Monit 2008 0.79
124 New concepts to individualize calcineurin inhibitor therapy in renal allograft recipients. Saudi J Kidney Dis Transpl 2010 0.79
125 Posttransplant sCD30 as a predictor of kidney graft outcome. Transplantation 2011 0.79
126 Monitoring immunosuppression with measures of NFAT decreases cancer incidence. Clin Immunol 2009 0.79
127 Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients. Liver Transpl 2011 0.79
128 Approaches towards individualized immune intervention. Dig Dis 2010 0.78
129 The extent of HLA-DR expression on HLA-DR(+) Tregs allows the identification of patients with clinically relevant borderline rejection. Transpl Int 2013 0.78
130 Plasmapheresis adjusts inflammatory responses in potential kidney transplant recipients. Transplantation 2013 0.78
131 Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant 2008 0.78
132 Deciphering the systems biology of mTOR inhibition by integrative transcriptome analysis. Curr Pharm Des 2014 0.78
133 The patient with C-ANCA/PR3-ANCA-positive crescentic pauci-immune glomerulonephritis and recurrence of nephritic sediment. Nephrol Dial Transplant 2008 0.77
134 Polar release of pathogenic Old World hantaviruses from renal tubular epithelial cells. Virol J 2012 0.77
135 European renal best practice guideline on the management and evaluation of the kidney donor and recipient. Nefrologia 2014 0.77
136 Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients. Clin Transplant 2008 0.77
137 A randomized trial of intensified vs. standard dosing for enteric-coated mycophenolate sodium in de novo kidney transplant recipients: results at 1 year. Clin Nephrol 2013 0.77
138 Prevention of antibody-mediated kidney transplant rejection. Transpl Int 2012 0.77
139 Pharmacodynamic disparities in tacrolimus-treated patients developing cytomegalus virus viremia. Ther Drug Monit 2011 0.77
140 The receptor for advanced glycation end-products (RAGE) plays a key role in the formation of nanotubes (NTs) between peritoneal mesothelial cells and in murine kidneys. Cell Tissue Res 2014 0.77
141 Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients. Pediatr Transplant 2010 0.77
142 Transmission of donor-derived small-cell carcinoma cells by a nontumor-bearing allograft. Transplantation 2005 0.77
143 Targeting activation of specific NF-κB subunits prevents stress-dependent atherothrombotic gene expression. Mol Med 2012 0.77
144 Cellular infiltrates and NFκB subunit c-Rel signaling in kidney allografts of patients with clinical operational tolerance. Transplantation 2012 0.77
145 The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial. Trials 2014 0.77
146 Psychosocial and physical outcome following kidney donation-a retrospective analysis. Transpl Int 2015 0.77
147 The role of pretransplant dialysis modality on renal allograft outcome. Nephrol Dial Transplant 2011 0.76
148 Comprehensive immunohistological analysis of the endothelin system in human kidney grafts. Nephrol Dial Transplant 2006 0.76
149 Targeting the retinoblastoma protein by MC007L, gene product of the molluscum contagiosum virus: detection of a novel virus-cell interaction by a member of the poxviruses. J Virol 2008 0.76
150 Does borderline kidney allograft rejection always require treatment? Transplantation 2010 0.76
151 Methylprednisolone treatment increases the proportion of the highly suppressive HLA-DR(+)-Treg-cells in transplanted patients. Transpl Immunol 2012 0.76
152 Kidney and hypertension-causes. Update 2003. Herz 2003 0.76
153 Desensitization of HLA-incompatible kidney recipients. N Engl J Med 2011 0.75
154 Response to A reassessment of the Survival Advantage of Simultaneous Kidney-Pancreas Versus Kidney-Alone Transplantation. Transplantation 2015 0.75
155 Hepatic and renal failure after anterior myocardial infarction induced apical ventricular septal defect. Case Rep Med 2011 0.75
156 Expanding the indications of pancreas transplantation alone. Pancreas 2014 0.75
157 Kidney transplantation in highly sensitized patients: are there options to overcome a positive crossmatch? Langenbecks Arch Surg 2011 0.75
158 Renal Function in Type 2 Diabetes Following Gastric Bypass. Dtsch Arztebl Int 2016 0.75
159 Successful deceased-donor kidney transplantation in crossmatch-positive patients with peritransplant plasma exchange and Rituximab. Transplantation 2009 0.75
160 Cell therapy for immunosuppression after kidney transplantation. Langenbecks Arch Surg 2015 0.75
161 Transmission of malignancy with solid organ transplants. Transplantation 2005 0.75
162 Transplantation of a severely lacerated liver--a case report with review of the literature. Clin Transplant 2009 0.75
163 ABO-incompatible transplantation--a safe way to perform renal transplantation? Nephrol Dial Transplant 2006 0.75
164 Absence of mismatch repair deficiency-related microsatellite instability in non-melanoma skin cancer. J Invest Dermatol 2011 0.75
165 Current pharmacotherapeutical options for the prevention of kidney transplant rejection. Expert Opin Pharmacother 2013 0.75
166 Increased cyclosporin a sensitivity in vivo in pediatric renal transplant recipients compared with adults. Ther Drug Monit 2012 0.75
167 Safe Administration of An Anti-PD-1 Antibody to Kidney-transplant Patients: 2 Clinical Cases and Review of the Literature. J Immunother 2017 0.75
168 Correlation between pharmacokinetics of tacrolimus and pharmacodynamics on NFAT-regulated gene expression in stable kidney transplant recipients
. Clin Nephrol 2016 0.75
169 Improved pulse wave velocity and renal function in individualized calcineurin-inhibitor treatment by immunomonitoring: the randomized controlled Calcineurin Inhibitor-Sparing (CIS) Trial. Transplantation 2017 0.75
170 How can the poor outcomes for diabetic dialysis patients be improved? Semin Dial 2004 0.75
171 Acquired Glanzmann's thrombasthenia variant and immune thrombocytopenia in a renal transplant recipient receiving tacrolimus. Thromb Haemost 2005 0.75
172 Renal cell cancer--a multimodal approach to preserving renal function and improving survival. Nephrol Dial Transplant 2011 0.75
173 Pulmonary cavernae in Wegener's granulomatosis. Nephrol Dial Transplant 2006 0.75
174 Compelling drug indications in diabetic and nondiabetic nephropathy. Curr Hypertens Rep 2004 0.75
175 Emerging drugs for the treatment of transplant rejection. Expert Opin Emerg Drugs 2011 0.75
176 Clinical impact of hepatitis C virus infection in the renal transplant recipient. Nephron 2002 0.75
177 Do we need screening for thrombophilia prior to kidney transplantation? Nephrol Dial Transplant 2004 0.75
178 Cardiovascular abnormalities and hypertension in the elderly dialysis patient. Semin Dial 2002 0.75
179 Blood pressure on dialysis: an ongoing controversy. Saudi J Kidney Dis Transpl 2008 0.75
180 The ongoing need for innovation in transplant medicine and surgery. Transplantation 2005 0.75
181 Association of pretransplant soluble glycoprotein 130 (sgp130) plasma levels and posttransplant acute tubular necrosis in renal transplant recipients. Transplantation 2009 0.75
182 Early conversion from cyclosporine to everolimus following living-donor kidney transplantation: outcomes at 5 years posttransplant in the randomized ZEUS trial. Clin Nephrol 2016 0.75
183 Lymphoid interstitial lung disease in a patient with acute tubulointerstitial nephritis and uveitis: a new facet of a rare syndrome? Am J Kidney Dis 2006 0.75
184 Evolution of allograft fibrosis and function in kidney transplant recipients: a retrospective analysis of stable patients under CNI and mTORi. Transpl Int 2015 0.75
185 Pathophysiology of cardiovascular disease and renal failure. Cardiol Clin 2005 0.75
186 Long-Term Follow-Up of Kidney Transplant Recipients With Polycystic Kidney Disease. Exp Clin Transplant 2015 0.75
187 Use of erythropoietin after solid organ transplantation. Nephrol Dial Transplant 2007 0.75
188 Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. Transpl Int 2014 0.75
189 Transplantation in type 1 diabetes. Nephrol Dial Transplant 2009 0.75
190 Monitoring of calcineurin inhibitors by NFATregulated gene expression in de novo renal allograft recipients on cyclosporine A. Clin Nephrol 2015 0.75
191 A generalized seizure in a renal allograft recipient. Nephrol Dial Transplant 2005 0.75